Observation of the Curative Effect of the Dexamethasone Vitreous Cavity Implant for the Treatment of Irvine-Gass Syndrome.

Yu Mao; Li Qin Gao; Li Yun Jia; Si Meng Hou; Yuan Yuan Xiao; Xi Wen JI; Shuang Wang

Return

Observation of the Curative Effect of the Dexamethasone Vitreous Cavity Implant for the Treatment of Irvine-Gass Syndrome.

Author: Yu MAO ¹ ; Li Qin GAO ¹ ; Li Yun JIA ¹ ; Si Meng HOU ¹ ; Yuan Yuan XIAO ¹ ; Xi Wen JI ¹ ; Shuang WANG ²
Author Information

1. Beijing Tongren Eye Center, Beijing Ophthalmology and Visual Science Key Lab, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
2. Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Ophthalmology and Visual Science Key Lab, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Publication Type:Journal Article
Keywords: Dexamethasone; Irvine-Gass Syndrome; Macular edema; Vitreous injection
MeSH: Male; Humans; Female; Middle Aged; Aged; Macular Edema/etiology*; Dexamethasone/therapeutic use*; Intraocular Pressure; Prostheses and Implants; Cataract
From: Biomedical and Environmental Sciences 2023;36(8):725-731
CountryChina
Language:English
Abstract: OBJECTIVE:To investigate the clinical efficacy of dexamethasone vitreous cavity implants (Ozurdex) for the treatment of macular edema (Irvine-Gass Syndrome) after cataract surgery.
METHOD:Eight patients (eight eyes) with Irvine-Gass syndrome were enrolled for vitreous injections with Ozurdex. The patients included six men (six eyes) and two women (two eyes) with a mean age of 67.12 ± 11.92 years. Changes in the patients best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure were compared before and after treatment.
RESULT:The mean visual acuity BCVA of the patients was 0.81 ± 0.26 before implantation, which improved to 0.20 ± 0.12, 0.13 ± 0.09, and 0.15 ± 0.13 at 2 weeks, 1 month, and 3 months after implantation, respectively ( P < 0.001). The patient's mean CMT before implantation was 703.00 ± 148.88 μm, and it reduced to 258.87 ± 37.40 μm, 236.25 ± 28.74 μm, and 278.00 ± 76.82 μm at 2 weeks, 1 month, and 3 months after implantation, respectively ( P < 0.001).
CONCLUSION:The dexamethasone vitreous cavity implant (Ozurdex) is a safe and effective treatment, which can effectively improve patient's visual acuity and reduce macular edema associated with cataract surgery.